What Meftal Treats: Main Uses and Benefits

Meftal (Mefenamic Acid) provides targeted symptomatic support across key domains, offering relief from symptoms related to physical discomfort and systemic imbalance.

The medication is commonly used across conditions presenting with acute episodes and recurrent manifestations.

---

Targeted Relief for Menstrual Discomfort and Symptoms

This medication is commonly used to help with relief for the severe, cramping pain known as primary dysmenorrhea. It is also applicable in cases of menorrhagia (excessive bleeding), and may assist with managing the flow and related discomfort. This action supports the patient during difficult episodes by easing distress, which may assist with maintaining functional stability during symptomatic periods.

---

Alleviating Acute Pain and Inflammation

Meftal is considered relevant across general domains where short-term symptomatic assistance is appropriate, helping to manage symptom clusters that may appear suddenly or fluctuate. It is applied to ease mild to moderate acute pain and concurrent inflammation arising from sources such as musculoskeletal injuries or discomfort following dental procedures. This provides supportive relief that may assist with maintaining functional stability when symptoms interfere with routine activities.

---

Symptomatic Management of Joint Conditions and Fever

The medication is applied across domains where additional symptomatic support is needed, contributing to easing distress in clinical settings marked by heightened discomfort. It is commonly used to help with managing the distressing manifestations of pain and inflammation in chronic conditions like osteoarthritis and rheumatoid arthritis. Furthermore, it plays a role in managing pyrexia (fever), which may assist with maintaining a sense of stability when symptoms are more noticeable.

---

Quick Fact: Relief for Acute and Chronic Discomfort

Indication Type	Key Conditions and Symptoms
Menstrual	Primary Dysmenorrhea (cramps), Menorrhagia (heavy flow)
Pain	Acute mild-to-moderate pain, Dental pain, Musculoskeletal injury
Inflammation	Osteoarthritis, Rheumatoid Arthritis, Post-injury swelling
Systemic	Pyrexia (Fever)

Regulatory References

1. NIH DailyMed official drug label

Eligibility Map: Who can and cannot use Meftal — official regulatory information

Mefenamic Acid eligibility is strictly governed by regulatory status (Contraindicated, Not Recommended, or Caution Required) based on age, medical history, and existing organ function.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and adolescents aged 14 years and older (for tablets/capsules). Use in children over six months may be allowed for fever in some regions.
Populations for whom use is contraindicated	Patients with a history of hypersensitivity to any NSAID (including aspirin); severe renal, hepatic, or heart failure; active GI bleeding/ulceration; or the third trimester of pregnancy.
Age-related eligibility rules	Use Not Established in children under 14 years (US label). Geriatric patients require careful dosage selection due to increased risk of gastrointestinal and renal adverse events.
Eligibility-related restrictions	Caution is required in patients with hypertension, pre-existing heart failure, renal impairment, or those who have undergone CABG surgery (use is prohibited peri-operatively). Not recommended for nursing mothers or women attempting to conceive.

Connection to the overall eligibility profile: Official prescribing information uses absolute contraindications to exclude populations with severe systemic disease or NSAID cross-sensitivity. Eligibility is otherwise conditional, requiring caution for specific risk groups like the elderly and those with cardiovascular or renal impairment.

Mefenamic Acid's interaction profile is structured around pharmacokinetic modifications, pharmacodynamic risks, and restrictions established in regulatory labeling. The medicine is formally contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. It is also restricted for patients with a history of allergic reactions to Aspirin or other NSAIDs.

Pharmacodynamically, co-administering Mefenamic Acid with Oral Anticoagulants (such as Warfarin) or anti-platelet agents like low-dose Aspirin enhances the risk of gastrointestinal and non-gastrointestinal bleeding and hemorrhage. The combination with other systemic NSAIDs, Corticosteroids, or SSRIs is also documented to increase the risk of GI toxicity.

For the hemodynamic system, the medication reduces the anti-hypertensive effect of ACE inhibitors, ARBs, and diuretics, potentially increasing the risk of renal impairment. The co-administration of Lithium leads to its decreased elimination, resulting in elevated plasma concentrations.

In terms of drug clearance, Mefenamic Acid is extensively metabolized by the CYP2C9 enzyme. Patients who are known or suspected to be poor CYP2C9 metabolizers may exhibit abnormally high plasma levels due to reduced clearance. The use of Antacids containing Magnesium Hydroxide is officially documented to significantly increase the absorption rate of Mefenamic Acid. Additionally, Alcohol is noted in official documents as an added risk factor for GI bleeding and perforation.

Mechanism of Action: Mefenamic Acid

The primary mechanism involves non-selective inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes. By blocking these key enzymes, Mefenamic Acid interrupts the conversion of arachidonic acid into lipid mediators known as prostaglandins. This action modifies the initial molecular step of the inflammatory cascade, resulting in a reduced concentration of chemical mediators that modulate peripheral nerve sensitization and influence local physiological fluid dynamics.

Pathway Modulation

The mechanism modulates specific enzyme activity that influences multiple physiological systems. It acts centrally to suppress prostaglandin E2 (PGE2) production in the hypothalamus, facilitating the return of the elevated temperature set-point toward basal levels. Furthermore, Mefenamic Acid modulates activity on uterine smooth muscle, where it limits the synthesis of PGE2 and PGF2alpha, which are mediators involved in driving muscle contractions. This dual peripheral and central modulation results in altered signaling dynamics within targeted physiological pathways.

How to Use Meftal: Official Administration Guidelines

Meftal, which contains Mefenamic Acid, is administered exclusively via the oral route. The standardized dosing protocol consists of specific amounts, frequency, duration, and context of administration.

---

Standard Dosing Regimens and Frequency

Therapy in adults begins with a 500 mg initial dose. This is followed by a maintenance dose of 250 mg, which is typically taken every six hours (Q6H) as needed. For conditions like chronic arthritis, a regimen of 500 mg taken three times daily (TID) may be used.

---

Duration and Treatment Cycle

Administration is constrained by explicit time limits. For the management of acute pain, the duration of therapy should generally not exceed seven days. When used for primary dysmenorrhea (menstrual pain), the treatment is considered cyclic, and administration should begin at the onset of symptoms or bleeding but is usually limited to two to three days per cycle. Clinical practice emphasizes the principle of using the lowest effective dose for the shortest possible duration.

---

Administration Conditions

To ensure proper intake, Mefenamic Acid should be taken with food or milk, a precaution used to minimize potential gastric discomfort. The medicine is available as capsules, tablets, and an oral suspension. The suspension form, used in pediatric cases, requires the bottle to be shaken well before the required dose is measured.

---

Population-Specific Use

While adult dosing is standardized, specific rules apply to younger populations. For acute pain and dysmenorrhea, use is generally not recommended in children under 14 years of age. In specific instances, the oral suspension may be used in children over six months, with dosing determined by body weight.

Recent Clinical Evidence Overview

Mefenamic acid (the active compound in Meftal) is a non-steroidal anti-inflammatory drug (NSAID) with established use in treating mild-to-moderate pain, including primary dysmenorrhea (menstrual pain). Recent research and clinical consensus papers have focused on characterizing its safety profile, use in specific populations, and potential applications beyond its primary indications.

---

Efficacy and Safety Profile

• Primary Dysmenorrhea: Open clinical trials continue to show that mefenamic acid significantly decreases pain scores from baseline during the menstrual cycle. Comparative studies have evaluated its effect against other agents, with some findings suggesting comparable outcomes for pain reduction.
• Post-Dental Pain: A randomized clinical trial found that mefenamic acid demonstrated marked efficacy in pain relief following dental extraction compared to another common analgesic, indicating its potent anti-inflammatory and analgesic action in this setting.
• Antipyretic Use: A recent consensus among pediatric experts evaluated mefenamic acid for fever management, citing evidence that supports its role as an effective antipyretic. Preclinical and limited clinical data also suggest potential activity against certain RNA viruses, which has prompted exploratory studies in viral infections.

---

Adverse Event Profile

Clinical trials have consistently reported the risk of serious adverse cardiovascular thrombotic events (like heart attack or stroke), gastrointestinal events (bleeding or ulceration), and renal impairment associated with the entire NSAID class, including mefenamic acid.

System	Study Finding
Hepatotoxicity	Transient elevations of liver enzymes were observed in a small percentage of patients in prospective studies, which typically resolved without dose modification.
Hypersensitivity	Regulatory agencies have issued communications underscoring the potential for severe, life-threatening allergic reactions, such as Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome.

Long-term safety data remains limited, particularly in the pediatric population, and use is generally not recommended for extended periods due to the risks associated with all NSAIDs.

Key Studies & References

1. Drug label and prescribing information for Mefenamic Acid (Ponstel)
2. Cardiovascular and gastrointestinal risk of nonsteroidal anti-inflammatory drugs: updated systematic review and meta-analysis

Common questions about Meftal (FAQ)

Q: What is Meftal used for?

A: Meftal, which contains mefenamic acid, is a type of medicine known as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is typically prescribed for:

• Relieving pain from various conditions, such as muscle pain, headaches, dental pain, and joint pain.
• Treating the pain and heavy bleeding associated with menstrual periods (dysmenorrhea and menorrhagia).

It works by stopping the body's production of certain substances that cause pain and inflammation.

Q: How long does Meftal take to work?

A: Meftal (mefenamic acid) usually starts working quickly, often within 30 minutes to an hour after taking a dose. The peak effect, when the medicine is working its best to relieve pain, is typically seen within 2 to 4 hours.

For sudden pain, it is often recommended to take a dose as soon as the pain starts.

Q: Can I take Meftal for a fever?

A: While mefenamic acid, the active ingredient in Meftal, does have antipyretic (fever-reducing) properties, it is not the primary or first-choice medicine for treating fever.

Doctors generally recommend paracetamol (acetaminophen) or ibuprofen for simple fever relief. Meftal is more commonly prescribed when the fever is accompanied by significant pain and inflammation, or when other standard treatments have not been effective. Always consult a doctor before using Meftal for a fever, especially in children.

Q: Is Meftal the same as paracetamol?

A: No, Meftal and paracetamol (also known as acetaminophen) are different medicines.

• Meftal contains mefenamic acid and belongs to the NSAID class. It reduces pain, inflammation, and fever.
• Paracetamol reduces pain and fever, but it does not significantly reduce inflammation.

They have different mechanisms of action and different side effect profiles. They should not be confused, and care should be taken when taking both, as directed by a healthcare provider.

Q: What are the common side effects of Meftal?

A: Like all NSAIDs, Meftal can cause side effects. The most common ones often affect the digestive system and may include:

• Stomach pain or discomfort
• Nausea and vomiting
• Indigestion (dyspepsia)
• Diarrhea

To help reduce the risk of stomach irritation, it is often advised to take Meftal with food, milk, or an antacid.

Q: Can I take Meftal on an empty stomach?

A: It is generally not recommended to take Meftal (mefenamic acid) on an empty stomach. Taking it with food, milk, or an antacid helps to coat the stomach lining and can significantly reduce the risk of common side effects, such as:

• Stomach pain
• Indigestion
• Nausea

If you experience persistent stomach issues, you must inform your doctor.

Storage and Disposal Requirements for Mefenamic Acid (Meftal)

Official Storage Conditions

Mefenamic acid must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F). The regulatory labeling mandates that the product be protected from excess heat and moisture, and it must be kept from freezing. The medication should remain in its tightly closed original container.

Child Safety and Disposal

It is an explicit regulatory requirement to keep this medication out of the sight and reach of children.

For disposal of unused or expired product, the preferred method is utilizing a drug take-back program. If a program is not available, the medication must be mixed with an undesirable substance (such as dirt) in a sealed container and placed in the household trash. This medication should not be flushed down the toilet.